Abstract
Reliable and scalable quantification of prion protein (PrP) is vital to the development of PrP-lowering drugs for prion disease. Here we develop a plate-based immunoassay reactive for PrP across six species of interest and applicable to brain and cerebrospinal fluid (CSF). Brain PrP shows similar patterns of regional variation in mice, cynomolgus macaques and humans. CSF PrP concentration does not appear to differ according to age, sex, or common PRNP variants, but it is reduced in the presence of rare pathogenic PRNP variants, with carriers of P102L displaying 55% and of D178N just 31% the CSF PrP concentration of mutation-negative controls. In rodents, pharmacologic reduction of brain Prnp RNA is reflected in brain parenchyma PrP, and in turn in CSF PrP. Our findings support the use of CSF PrP as a pharmacodynamic biomarker for PrP-lowering drugs, and suggest that relative reduction from individual baseline CSF PrP concentration may be an appropriate marker for target engagement.
Competing Interest Statement
EVM has received consulting fees from Deerfield Management and has received research support in the form of unrestricted charitable contributions from Ionis Pharmaceuticals. SMV has received speaking fees from Ultragenyx, Illumina, and Biogen, and has received research support in the form of unrestricted charitable contributions from Ionis Pharmaceuticals. SEA has received honoraria and/or travel expenses for lectures from Abbvie, Biogen, EIP Pharma, Roche, and Sironax; has received fees for consulting and/or advisory boards from Athira, Biogen, Cassava, Cognito, Cortexyme, Sironax, and vTv; and has received grant support from Abbvie, Amylyx, EIP Pharma, Ionis Pharmaceuticals, and Merck. HTZ, CM, JM, and HBK are employees and shareholders of Ionis Pharmaceuticals. MRM is an employee of Bioagilytix. EK is an employee of Kymera. JL is currently an employee of Kriya Therapeutics. DEC has received grant support from Ionis Pharmaceuticals.
Funding Statement
This study was funded by Prion Alliance, CJD Foundation (the Michael H. Cole, Cheryl Molloy, Jose A. Piriz and Sonia E. Piriz, Jeffrey A. Smith, and Mercies in Disguise Memorial Grants), Ionis Pharmaceuticals (internal efforts and support to DEC), the Broad Institute (including direct philanthropic donations to Prions@Broad), the National Institutes of Health (R21 TR003040 to SEA), Ono Pharma Foundation, and an anonymous organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Partners Healthcare IRB gave ethical approval for this work (protocol #2017P000214).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data and source code sufficient to reproduce the figures and analyses herein are available in the online git repository of this study with the exception of sensitive patient data, which are available upon reasonable request to the authors.